South African Tuberculosis Vaccine Initiative (SATVI)   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cape Town South Africa (2001)

Organization Overview

First Clinical Trial
2001
NCT00242047
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

South African Tuberculosis Vaccine Initiative | Study Principal Investigator South African Tuberculosis Vaccine Initiative

Active Ingredients

Drugs in Phase 4 Trials (1)

bacille calmette-guerin (5 trials)

Drugs in Phase 3 Trials (2)

isoniazid (nydrazid) (1 trial)

rifapentine (priftin) (1 trial)

Drugs in Phase 2 Trials (7)

candida albicans allergen (Candin) (1 trial)

gla-se (2 trials)

h56 (1 trial)

ic31 (1 trial)

id93 (2 trials)

mtbvac (4 trials)

mva85a (1 trial)

Drugs in Phase 1 Trials (2)

caf®10b (1 trial)

h107e (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infections (Phase 2)

Latent Tuberculosis (Phase 2)

Tuberculosis (Phase 4)

Tuberculosis, Pulmonary (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 12